Abstract Details

Title Variability of Epstein-Barr Virus Activity and the Anti-EBV Immune Response in Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P05 - (-)

Poster/Presentation
Number 163

Objective

Background BACKGROUND: EBV infection is associated with MS, but it is not clear whether EBV plays a causal role. After resolution of primary EBV infection, the virus remains present in a latent state in B lymphocytes. The hypothesis of this work is that intermittent reactivation of EBV infection drives a cross-reactive immune response which causes the recurrent myelin damage in MS.

Design/Methods DESIGN/METHODS: Blood and saliva samples are collected every two weeks for 16 weeks from patients with active, early MS. MRI scans are done every 4 weeks. EBV DNA concentrations are measured in the peripheral blood mononuclear cells, plasma, and saliva using quantitative PCR. The immune response against EBV is measured as lymphocyte proliferation to purified EBV, proliferation against autologous EBV-infected cells, and ELIspot with EBV.

Results RESULTS: Complete results are available for two subjects. Cellular proliferation to EBV and EBV-infected cells is persistently high in both subjects, but fluctuates over time. Proliferation to EBV ranged from 11% to 57% of the response to anti-CD3 antibody stimulation for one subject, and from 29% to 53% in the second. The number of cells secreting interferon-? in response to EBV also fluctuates over time. The anti-EBV response was significantly higher than the response to tetanus or varicella. Both subjects had detectable EBV DNA in plasma at one of the 9 time points, but this did not correlate with the observed changes in the EBV response. This work is ongoing, and data from additional subjects will be presented.

Conclusions CONCLUSIONS: The anti-EBV immune response in MS is vigorous, but varies over time. EBV infection in MS is well controlled, since EBV DNA is rarely detectable. This study should be able to detect any correlation between EBV activity and MS disease activity.

Authors/Disclosures
John W. Lindsey, MD (University of Texas Health Science Center At Houston) PRESENTER	Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Banner Life Sciences. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mapi. Dr. Lindsey has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Teva. The institution of Dr. Lindsey has received research support from Genentech.
	No disclosure on file
Merit E. Cudkowicz, MD, MSC, FAAN (Massachusetts General Hospital)	Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for cytokinetics. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for immunitypharm. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for transposon. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quralis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for vectorY. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for inflectis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ono. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for otsuka. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for coya. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ac immune. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for pontifax. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inflectis. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for ab science. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for aclipse. Dr. Cudkowicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Locust Walk. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pasithea. Dr. Cudkowicz has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Praxis Precision Medicine. Dr. Cudkowicz has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology . The institution of Dr. Cudkowicz has received research support from NINDS. The institution of Dr. Cudkowicz has received research support from ALSFAC. The institution of Dr. Cudkowicz has received research support from UCB ra. The institution of Dr. Cudkowicz has received research support from Biohaven. The institution of Dr. Cudkowicz has received research support from Clene nanomedicine. The institution of Dr. Cudkowicz has received research support from prilenia. The institution of Dr. Cudkowicz has received research support from ALS one. The institution of Dr. Cudkowicz has received research support from Seelos. The institution of Dr. Cudkowicz has received research support from Calico. The institution of Dr. Cudkowicz has received research support from denali. The institution of Dr. Cudkowicz has received research support from ITB. The institution of Dr. Cudkowicz has received research support from PharmAust. The institution of Dr. Cudkowicz has received research support from woolsley. Dr. Cudkowicz has received research support from lilly. The institution of Dr. Cudkowicz has received research support from J& J. Dr. Cudkowicz has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��